Trials / Completed
CompletedNCT00067314
Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy
A Phase II Study Of Intravenous Edotecarin (PHA-782615) In Patients With Anthracycline- And Taxane Resistant Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This international study will study how metastatic breast cancer responds to the investigational drug treatment, what are the side effects of the investigational drug when given to women with metastatic breast cancer and how often do these side effects occur. The study will also analyze how fast investigational drug and its breakdown products are cleared from the blood in these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Edotecarin |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2003-08-18
- Last updated
- 2012-01-18
Locations
19 sites across 4 countries: United States, Australia, Belgium, France
Source: ClinicalTrials.gov record NCT00067314. Inclusion in this directory is not an endorsement.